GMM Pfaudler Likely Key Beneficiary of Capex Uptrend in Chemical, Pharma Industries -- Market Talk

Dow Jones01-13

0621 GMT - GMM Pfaudler is likely a key beneficiary of a capital-expenditure uptrend in the chemical and pharmaceutical industries, Ambit Capital analysts say in a research report. They initiate coverage of the stock with a buy rating and a target price of INR2,300.00. During FY 2016-2023, the glass-lined equipment manufacturer delivered 25% revenue CAGR, driven by capex from chemical and active pharmaceutical ingredients players, the analysts note. Given the uptick in capex and continued growth in the non-glass-lined equipment business, GMM Pfaudler's growth and margins will likely be revived in FY 2026-2027, the analysts add. The brokerage forecasts 10% revenue CAGR over FY 2025-2028. Shares are 2.0% lower at INR1,190.75. (ronnie.harui@wsj.com)

 

(END) Dow Jones Newswires

January 13, 2025 01:21 ET (06:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment